Approaches to the management of SCD. Of the disease-modifying therapies, 4 drugs, hydroxyurea, L-glutamine, crizanlizumab, and voxelotor, are currently approved by the FDA. In the absence of long-term data, gene therapy and gene editing are referred to as “potentially curative therapies.”